Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Plant-made H7 VLP Influenza Vaccine in Adults
NCT02022163Phase 1Completed
- Sponsor
- Medicago Inc.
- Start
- Dec 2013
- Primary completion
- Sep 2014
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of H7 VLP vaccine (5 arms), sponsored by Medicago Inc. Primary endpoints: Safety and Tolerability at 6 months and Immunogenicity. Started Dec 2013; status: completed.
02
Drugs
H7 VLP vaccine
Beyond the preview
Go deeper on NCT02022163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022163.